Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
23 mai 2024 17h30 HE
|
Elicio Therapeutics, Inc.
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
15 mai 2024 16h30 HE
|
Elicio Therapeutics, Inc.
ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading...
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
25 avr. 2024 08h30 HE
|
Elicio Therapeutics, Inc.
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
05 avr. 2024 16h30 HE
|
Elicio Therapeutics, Inc.
68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated...
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
29 mars 2024 08h30 HE
|
Elicio Therapeutics, Inc.
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR...
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
18 mars 2024 08h00 HE
|
Elicio Therapeutics, Inc.
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
06 mars 2024 08h30 HE
|
Elicio Therapeutics
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
06 juin 2023 08h00 HE
|
Elicio Therapeutics
Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchangePositive Phase 1 clinical data was recently presented at ASCO 2023 for the 2-peptide formulation of...
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
03 juin 2023 09h00 HE
|
Elicio Therapeutics
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete...
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
02 juin 2023 16h30 HE
|
Elicio Therapeutics
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today...